News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 29, 2024

Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Author(s)Ryan Haumschild, PharmD, MS, MBA, Roy Beveridge, MD, Brian T. Hill, MD, PhD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

Episodes in this series

A panel of 4 experts on CLL

EP. 1 Recent Trends and Innovations in the Management of CLL

A panel of 4 experts on CLL

EP. 2 CLL Treatment Landscape: Overview of BTK Inhibitors

A panel of 4 experts on CLL

EP. 3 Evaluating Value of BTK Inhibitors in CLL Treatment

A panel of 4 experts on CLL

EP. 4 Factors Influencing Choice of Second-Generation BTKi Monotherapy

A panel of 4 experts on CLL

EP. 5 Empowering Patients: Key Considerations for BTK Inhibitor Adherence

A panel of 4 experts on CLL

EP. 6 Optimizing Therapy Sequencing in CLL

A panel of 4 experts on CLL

EP. 7 Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

A panel of 4 experts on CLL

EP. 8 Decision-Making in CLL: The Role of Real-World Evidence

A panel of 4 experts on CLL

EP. 9 Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

A panel of 4 experts on CLL

EP. 10 Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

A panel of 4 experts on CLL

EP. 11 Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

A panel of 4 experts on CLL

EP. 12 The Inflation Reduction Act: Implications for Patient Access in CL

A panel of 4 experts on CLL

EP. 13 Patient Access Advocacy for BTK Inhibitors

A panel of 4 experts on CLL

EP. 14 Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following question(s):

How do you choose between BTK inhibitors in patients with relapsed/refractory (R/R) CLL?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Acalabrutinib | Image Credit: © Сергей Шиманович-stocka.dobe.com.jpeg

Real-World Evidence Backs Acalabrutinib in CLL Care

ByMaggie L. Shaw

February 6th 2026

Margaret Krackeler, MD

The Value of Real-World Data in CLL: Margaret Krackeler, MD

ByRose McNulty,Margaret Krackeler, MD

February 4th 2026

Margaret Krackeler, MD

Real-World Data Support Zanubrutinib Use in Older Patients With CLL: Margaret Krackeler, MD

ByRose McNulty,Margaret Krackeler, MD

January 31st 2026

Margaret Krackeler, MD

Perspectives on Zanubrutinib Adoption for CLL Treatment: Margaret Krackeler, MD

ByRose McNulty,Margaret Krackeler, MD

January 29th 2026

CLL-SLL image | Image Credit: © Saiful52-stock.adobe.com

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

ByMaggie L. Shaw

January 28th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

5 Things to Know About the Oral GLP-1 Era

Stroke Subtype Does Not Affect Efficacy of Asundexian for Second Stroke Prevention

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text